Abstract
The unusually rapid development of large-scale vaccines against coronavirus disease 2019 (COVID-19) was a historical moment for clinical healthcare. However, it took precedence over the fundamental immunological work needed for a fuller understanding of the critical components of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Consequently, almost all studies of the immune response in COVID-19 have focused exclusively on serum antibodies and systemic cell-mediated immunity including innate responses [1].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
